The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Roads for CAR-T: Strategies for Cell Based ATMPs | With a small number of approved cell therapies/ ex-vivo gene therapies and with those approved therapies reaching small patient populations there is not a proven strategy for successful large-scale commercial manufacturing. This session will briefly introduce different strategies for commercial manufacturing (e.g. centralized, regionalized, point of care, outsourced). Then move into a panel discussion to hear how various companies are pursuing commercialization and gain insights into the opportunities of these strategies. As a result of this session participants will hear from industry leaders about the regulatory, supply chain, and process technology enabling different visions of future CAR-T manufacturing.
Speaker(s):
Eytan
Abraham,
Head of Personalized Medicine Business Unit,
Lonza
Erich
H. Bozenhardt,
Associate Director Process Engineering, Regenerative Medicine,
United Therapeutics